News & Media

Donate Online
Donate By Post
Donate By Standing Order

We will post LHON news & events on this page. 

Minutes of the LHON Society 2017 AGM

Click here to view


LHON Society perspective on the European Commission authorisation of Raxone

Click here to view



GenSight LHON Gene Therapy Clinical Trials

GenSight Biologics has launched two pivotal Phase 3 clinical trials of its gene therapy product GS010 for patients with Leber hereditary optic neuropathy (LHON) carrying the 11778 mitochondrial DNA mutation. Moorfields Eye Hospital in London is now actively recruiting for the UK with Mr Patrick Yu Wai Man (Consultant Ophthalmologist) as the lead investigator.

The main inclusion criteria:

(1) Confirmed LHON with the 11778 mitochondrial DNA mutation

(2) Disease duration of less than 12 months (in both eyes)

(3) Age 18 years or older

Travel expenses and accommodation in London will be fully covered. 

Further details can be found in this press release on the GenSight website

Information on the clinical trials can also be found here on the Clinicaltrials.gov website



25th June 2015 EMA Statement on Raxone (Idebenone)

Click here to view



Videos from the 2015 LHON Washington UMDF Conference

Click here to view



Bascom Palmer Eye Institute LHON gene therapy clinical trial (initial results)

Click here to view